Kumamoto University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Kumamoto Japan (1925)

Organization Overview

First Clinical Trial
2001
NCT00265239
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Department nephrology Kumamoto University | Department of Cardiovascular Clinical and Translational Research, Kumamoto University Hospital | Department of Cardiovascular Medicine, Faculty of Life Sciences, Kumamoto University | Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University | Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University | Department of Ophthalmology, Kumamoto University Graduate School & Medical Sciences | Department of Pharmacology and Molecular Therapeutics, Graduate School of Medical Sciences, Kumamoto University | Graduate School of Medical Sciences Kumamoto University | Health Care Center / Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University | Kumamoto University | Kumamoto University Graduate School of Medical Sciences | Kumamoto University, Graduate School of Medical Sciences | Kumamoto University Hospital | Professor of Medicine, Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University | Saiseikai Kumamoto Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Anemia (Phase 4)

Anemia, Iron-Deficiency (Phase 4)

Arteriosclerosis (Phase 4)

Atherosclerosis (Phase 4)

Breast Neoplasms (Phase 3)

Cardiovascular Diseases (Phase 4)

Colorectal Neoplasms (Phase 2)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Dyslipidemias (Phase 4)

Fatigue (Phase 2)

Hypercholesterolemia (Phase 4)

Hypertension (Phase 4)

Infarction (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Leukemia (Phase 2)

Leukemia-Lymphoma, Adult T-Cell (Phase 2)

Leukemia, T-Cell (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Renal Insufficiency (Phase 4)

Reperfusion Injury (Phase 4)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 34